ndoscopic ultrasound (EUS) with fine needle aspiration (FNA) is the standard diagnostic procedure for tissue sampling of solid lesions within adjacent to the GI tract. However, FNA has limitations that can eliminated if a larger tissue sample is obtained. A fine needle biopsy (FNB) device that has a reverse bevel at the needle tip may provide higher diagnostic yield with fewer needle passes.
Two randomized controlled trials (RCT) compared the diagnostic yield of EUS-FNA and EUS-FNB for pancreatic and non-pancreatic solid lesions. In their study entitled, "Analysis of Fine-Needle Biopsy vs Fine-Needle Aspiration in Diagnosis of Pancreatic and Abdominal Masses: a Prospective, Multicenter, Randomized Controlled Trial," Cheng and colleagues 1 conducted a large, multicenter study in 5 tertiary care centers in China. They used 22-gauge needles for both FNA (EchoTip Ultra Needle; Cook Medical, Bloomington, IN) and FNB (EchoTip ProCore Needle, Cook Medical) to sample tissue from pancreatic and non-pancreatic solid masses >1 cm in size. Lesions were sampled with four passes using the slow pull technique for the first 2 passes and a suction technique for the latter two passes. Crossover to the alternative needle was not performed. The study randomized 408 patients with a solid mass (>1 cm) in the pancreas, abdomen, mediastinum, or pelvic cavity to undergo FNA (n ¼ 190; mean age, 58 y) or FNB (n ¼ 187; mean age, 58 y). Patients were followed up at weeks 1, 12, and 48, and final diagnoses were obtained after surgery, imaging analysis, or resolution of lesion.
For all lesions, the diagnostic yield of FNB was 91.4% which was significantly higher than the 80% yield with FNA (P ¼ .0015). Subgroup analysis found that FNB had a higher diagnostic yield than FNA for pancreatic masses, lesions over 20 mm in size, and those located in the head or uncinate process. The percentage of tissue integrity was significantly higher with FNB vs FNA group (90.32% vs 80.34%; P ¼ .0233). There was no significant group difference in adverse events.
Based on the results of this study, the investigators concluded that EUS-FNB using a 22 gauge histology needle was superior for histologic diagnostic yield compared to the same size standard FNA needle for pancreatic lesions but not for nonpancreatic masses.
A second RCT by Nagula et al 2 was conducted at 6 tertiary care centers in the United States in the article entitled, "Comparison of endoscopic ultrasound-fine-needle aspiration and endoscopic ultrasound-fineneedle biopsy for solid lesions in a multicenter, randomized trial." The aim of this study was to compare the diagnostic yield between EUS-guided FNA and FNB and to examine the number of needle passes needed to obtain a cytological diagnosis. FNA (EchoTip, Cook Medical; Expect, Boston Scientific, Natick, MA) and FNB (EchoTip Procore, Cook Medical) were performed using either a 22-gauge or 25-gauge needle at the discretion of the endoscopist. For FNA, a stylet with negative suction was used during the first needle pass. For FNB, the slow pull technique was used for all passes. There was a difference in the needle size between the FNA and FNB groups. A 25-gauge FNA needle was used in 67.4% and a 22-gauge FNA needle was used in 32.6%. A 25-gauge FNB needle was used in 41.0% and a 22-gauge FNB needle was used in 59.0%. Rapid on-site cytological evaluation (ROSE) was utilized in 81.8% of cases. If ROSE was used, consecutive needle passes were made until the specimen was deemed adequate. If a diagnostic sample was not obtained by the 4th needle pass, crossover to the other needle was performed at the discretion of the endoscopist. If ROSE was not used, 4 needle passes were made.
The study population was comprised of 274 adults (47.8% women; mean age, 66.5 years) who were randomized to FNA (n ¼ 135; 49.3%) or FNB (n ¼ 139; 50.7%). Solid masses were the most common lesions sampled (76.6%) and most of these were located in the pancreas (83.7%). The other lesions sampled were lymph nodes (16.8%) located most commonly in the porta hepatitis and submucosal tumors (SMT; 6.6%) which were predominantly located within the stomach. The majority of patients had malignant lesions (70.1%; n ¼ 192), while others were found to have reactive lymphadenopathy (n ¼ 30; 11.0%) or spindle cell tumors (n ¼ 24; 8.8%). The diagnostic yield of FNA (91.1%) was similar to that of FNB (88.5%). No group differences were seen if results were stratified by the presence of on-site cytopathology or by type of lesion sampled. A similar number of passes (median of 1) were needed for a diagnostic sample for FNA and FNB.
In this rigorously designed multicenter trial, the investigators concluded that FNA and FNB had a similar diagnostic yield for pancreatic and non-pancreatic solid lesions with a comparable number of needle passes.
In summary, these two well designed RCTs showed differences in the comparative diagnostic yield of EUS-guided FNA and FNB for pancreatic solid masses although there were some methodologic differences between the studies. Both showed similar diagnostic yield of FNA and FNB for non-pancreatic lesions although there were a relatively lower number of these lesions in both studies. As noted by Nagula and 
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ith the annual cost of inpatient and ambulatory care of gastrointestinal (GI) and chronic liver diseases being over $103 billion dollars, identifying patients at high risk for frequent hospitalizations and long hospital stays is vital to improving population health and reducing healthcare costs. The aims of this study were to estimate the annual burden and costs of hospitalization in patients with chronic GI and liver diseases, and identify characteristics of high-need, highcost patients. 3 Using the Nationwide Readmissions Database (NRD) 2013, an all-payer longitudinal database of hospital inpatient stays that captures over 85% inpatient discharges from 21 state inpatient databases, the days spent in hospital/ month and estimated hospitalization costs were measured in a cohort of adult patients with common chronic GI and liver diseases. These included inflammatory bowel diseases (IBD), chronic liver diseases (CLDs), functional gastrointestinal disorders (FGIDs), GI hemorrhage, and pancreatic diseases. The study also identified characteristics associated with high-need, high-cost patients (top decile of total number days spent in hospital/month).
Of almost 11 million discharge records analyzed, 47,402 patients with IBD (n ¼ 47,402), CLDs (n ¼ 376,810), FGIDs (n ¼ 351,583), GI hemorrhage (n ¼ 190,881), or pancreatic diseases (n ¼ 98,432) were admitted to the hospital at least once between January to June 2013. The monthly length of hospital stay and costs were highest for patients with CLDs and FGIDs. Patients in the highest decile spent a median of 3.7-5.1 days/month in the hospital, had one hospitalization every 2 months with hospitalization costs averaging between $7438 to 11,425/ month. The leading causes for hospitalization were GI diseases, infections, and cardiopulmonary causes. Risk factors for 'high-need, high-cost' patients were Medicare/Medicaid insurance, lower income status, index hospitalization in a large rural hospital, high comorbidity burden, obesity, and infection-related hospitalization.
In summary, this nationally representative study found significant variability in the burden of hospitalization across patients with IBD, CLDs, FGIDs, gastrointestinal hemorrhage and pancreatic diseases. A small fraction of high-need, high-cost patients contributed disproportionately to hospitalization costs.
See page 1284.
Model for Identifying Individuals at Risk for Esophageal Adenocarcinoma T he incidence of esophageal adenocarcinoma (EAC) is increasing in Western populations and prognosis is poor because patients frequently present with advanced disease. Thus, models that can identify patients at risk for EAC and improve early detection are needed. This cohort study used prospectively collected data from the United Kingdom Biobank to create a risk-prediction model for EAC development within 5 years. 4 In this study, 355,034 individuals aged !50 years without a history of cancer prior to or within 6 months following baseline and with complete information on relevant risk factors were included. Demographic, lifestyle, and baseline medical factors were used to create a model to identify individuals at risk for EAC. Model performance was assessed using area under the receiver operating characteristics curve (AUROC), sensitivity, and specificity analyses.
Of the 355,034 individuals in the cohort who met inclusion criteria, 220 were diagnosed with EAC within 5 years. Individuals with EAC were more likely to be older, male, and a current or former smoker, and have a higher BMI and history of esophageal condition or treatments. These factors were used to develop a model (AUROC, 0.80; 95% CI, 0.77-0.82) and a scoring system with cut off points that predicted risk for EAC in 104,723 individuals (29.5%), including 170 of the 220 patients diagnosed with EAC. This scoring system identified individuals who developed EAC with a 77.4% sensitivity and 70.5% specificity. The 5-year risk of EAC was 0.16% for individuals with scores above the threshold and 0.02% for individuals with scores below the threshold. These results should be validated in other populations as the use of the UK Biobank may not be generalizable to the general population due to the healthy participant effect. and/or surgery, most commonly ileocolic resection (ICR), is needed. The aim of this retrospective study was to compare treatment outcomes (post-procedure morbidity and surgery-free survival) of upfront ICR vs EBD in CD patients with primary distal ileum strictures. 5 Of the consecutive CD patients treated at a single institution from 2000 to 2016, 375 patients met study inclusion criteria; 117 patients were treated with primary EBD and 258 patients were treated with primary ICR. In the EBD group, immediate technical success rate was 86.3%. Post-procedural adverse events and symptomatic improvement were more common after primary ICR than EBD (32.2% vs 4.7%, P < .0001; and 88.4% vs 54.4%, P < .0001, respectively). Patients undergoing upfront ICR had more frequent disease-related hospitalizations (30.2% vs 18.8%, P ¼ .02) but had a decreased rate of subsequent surgery than those receiving initial EBD (21.7% vs 45.3%, P < .0001). Surgery-free survival was significantly longer for patients who underwent ICR (11.1AE0.6 y vs 5.4AE0.6 y, P < .0001). In patients who had upfront EBD, reduced surgery-free survival was associated with increased stricture length, ileocolonic vs ileal disease, and decreased interval between EBD procedures.
In summary, this single institution retrospective study shows that EBD can play a therapeutic role in properly selected patients and can be successful in delaying surgery in a small proportion of patients long-term. However, ICR was generally a more durable treatment for primary ileocolic CD strictures.
See page 1260.
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